Page 454 - Traité de chimie thérapeutique 6 Médicaments antitumoraux

410 MEDICAMENTSINDUISANT OUSTABILISANTDES COUPURES DE L'ADN

BINASCHI M. et al., In vivo site specificity and human isoenzyme selectivity of two topoi-
somerase Il-poisoning anthracyclines, Cancer Res., 2000, 60, 3770-3776.
ETIEVANT C. et al., F 11782, a dual inhibitor of topoisomerases I and Il with an original
mechanism of action in vitro, and markedly superiorin vivo antitumour activity, relative
to three other dual toposisomerase inhibitors, intoplicin, aclarubicin, and TAS-103,
Cancer Chemother. Pharmacol., 2000, 46, 101-113.
RAMU A. et al., The riboflavin-mediated photooxidation of doxorubicin, Cancer Chemo-
ther. Pharmacol., 2000, 46, 449-458.
INDICATIONS, EFFETS SECONDAIRES
BERTAZZOLI C. et al., Adriamycin : toxicity data, Experientia, 1970, 15, 389-390.
MATHE G. et al., An oriented phase Il trial of THP-adriamycin in breast carcinoma, Bio-
med. Pharmacother., 1986, 40, 376-379.
WADLER S. et al., Lethal and sublethal effects of the combination of doxorubicin and the
bisdioxopiperazine, (+)-1,2-bis (35-dioxopiperazinyl-1-yl) propane (ICRF-187), on
murine sarcoma S180 in vitro, Biochem. Pharmacol., 1987, 36, 1495-1501.
SHAPIRO C. L. et al., Cardiac effects of adjuvant doxorubicin and radiation therapy in
breast cancer patients, J. Chem. Oncology, 1998, 16, 3493-3501.
WESSEL 1. et al., Human small cell lung cancer NYH cells selected for resistance to the
bisdioxopiperazine topoisomerase Il (topo Il) catalytic inhibitor ICRF-187 (NYH/187)
demonstrate a functional Arg162Gln mutation in the Walker A consensus ATP binding
site of the isoform, Proc. Am. Assac. Cancer Res., 1998, 39, 2552-.
WISEMAN L. R., SPENCER C. M., Dexrazoxane : A review of its use a cardioprotective
agent in patients receiving anthracycline-based chemotherapy, Drugs, 1998, 56, 385-
403.
RICHE C. et al., Pharmacovigilance : les leucémies secondaires, Eurocancer2000, 237-
238.
van ACKER F., Synthetic flavonoids as protectors against doxorubicin-induced
cardiotoxicity : VUF 5434, a more potent compound than monoHER. Clin. Cancer
Res., 2000, 6S ; Proceedings of the 2000 NCIEORTC·AACR Symposium, Abstract
362.
KIYOMIYA K.I. et al., Differences in intracellular sites of action of adriamycin ln neoplastic
and normal differentiated cells, Cancer Chemother. Pharmacol., 2001, 47, 51-56.
PEREGO P. et al., Role of apoptosis and apoptosis-related genes in cellular response
and antitumor efficacy of anthracyclines, Current Med. Chem., 2001, 8, 31-37.